© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 23, 1745-1757,
December 4, 2002
© 2002 Oxford University Press
ARTICLE |
Using Cyclooxygenase-2 Inhibitors as Molecular Platforms to Develop a New Class of Apoptosis-Inducing Agents
Affiliations of authors: J. Zhu, H.-P. Lin (Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy), D. C. Young (Biostatistics Core, Comprehensive Cancer Center), The Ohio State University, Columbus; X. Song, Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington; S. Yan, V. E. Marquez, Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD; C.-S. Chen, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, and Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky.
Correspondence to: Ching-Shih Chen, Ph.D., College of Pharmacy, The Ohio State University, 336 Parks Hall, 500 W. 12th Ave., Columbus, OH 43210–1291 (e-mail: chen.844{at}osu.edu).
Background: The cyclooxygenase-2 (COX-2) inhibitor celecoxib is thought to act as a chemopreventive agent by sensitizing cancer cells to apoptotic signals. Other COX-2 inhibitors, such as rofecoxib, are two orders of magnitude less potent than celecoxib at inducing apoptosis. The molecular structures of celecoxib and rofecoxib were used as starting points to examine the structural features that contribute to this discrepancy. Methods: We used a systematic chemical approach to modify the structures of celecoxib and rofecoxib to produce a series of compounds that were tested for their effects on the viability of human prostate cancer PC-3 cells and their ability to induce apoptosis in these cells. Cell viability was measured by the trypan blue dye exclusion assay, and apoptosis was measured by an enzyme-linked immunosorbent assay that quantifies DNA cleavage and by western blot detection of poly(ADP-ribose) polymerase (PARP) cleavage. Western blotting was used to monitor the effects of the compounds on phosphorylation of the serine/threonine kinase Akt and extracellular signal-regulated kinase 2 (ERK2), two components of celecoxib-induced apoptosis signaling. Monte Carlo simulations were used to molecularly model the surface electrostatic potential and electron density of selected compounds. All statistical tests were two-sided. Results: The structural requirements for the induction of apoptosis in PC-3 cells were different from those for COX-2 inhibition. Structure–function analysis indicated that the induction of apoptosis by compounds derived from COX-2 inhibitors required a bulky terminal phenyl ring, a heterocyclic system with negative electrostatic potential, and a benzenesulfonamide or benzenecarboxamide moiety. These derivatives mediated apoptosis by facilitating the dephosphorylation of Akt and ERK2, irrespective of their COX-2 inhibitory activities. Conclusion: A new class of compounds that induce apoptosis by targeting Akt and ERK2 signaling pathways in human prostate cancer cells can be synthesized by modifying existing COX-2 inhibitors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y.-H. Tan, K.-H. Lee, T. Lin, Y.-C. Sun, H. M. Hsieh-Li, H.-F. Juan, and Y.-C. Wang Cytotoxicity and Proteomics Analyses of OSU03013 in Lung Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1823 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen, X. Liu, P. Yue, A. H. Schonthal, F. R. Khuri, and S.-Y. Sun CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non Small-Cell Lung Cancer Cells Mol. Pharmacol., November 1, 2007; 72(5): 1269 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zhang, A. Suvannasankha, C. D. Crean, V. L. White, A. Johnson, C.-S. Chen, and S. S. Farag OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms Clin. Cancer Res., August 15, 2007; 13(16): 4750 - 4758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Schonthal Induction of Apoptosis by Celecoxib in Cell Culture: An Uncertain Role for Cyclooxygenase-2 Cancer Res., June 1, 2007; 67(11): 5575 - 5576. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pyrko, A. Kardosh, Y.-T. Liu, N. Soriano, W. Xiong, R. H. Chow, J. Uddin, N. A. Petasis, A. K. Mircheff, R. A. Farley, et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib Mol. Cancer Ther., April 1, 2007; 6(4): 1262 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, P. Yue, A. H. Schonthal, F. R. Khuri, and S.-Y. Sun Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells Cancer Res., December 1, 2006; 66(23): 11115 - 11119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy. Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M. Backhus, E. Sievers, G. Y. Lin, R. Castanos, R. D. Bart, V. A. Starnes, and R. M. Bremner Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors. Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Mohammed, D. Dhawan, S. Abraham, P. W. Snyder, D. J. Waters, B. A. Craig, M. Lu, L. Wu, R. Zheng, J. Stewart, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol. Cancer Ther., February 1, 2006; 5(2): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib Blood, December 15, 2005; 106(13): 4330 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Backhus, N. A. Petasis, J. Uddin, A. H. Schonthal, R. D. Bart, Y. Lin, V. A. Starnes, and R. M. Bremner Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, P. Yue, Z. Zhou, F. R. Khuri, and S.-Y. Sun Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells J Natl Cancer Inst, December 1, 2004; 96(23): 1769 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-C. Yang, C.-S. Chen, and C.-S. Chen Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms Mol. Cancer Ther., December 1, 2004; 3(12): 1671 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. El-Rayes, S. Ali, F. H. Sarkar, and P. A. Philip Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines Mol. Cancer Ther., November 1, 2004; 3(11): 1421 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Roychowdhury, R. A. Baiocchi, S. Vourganti, D. Bhatt, B. W. Blaser, A. G. Freud, J. Chou, C.-S. Chen, J. J. Xiao, M. Parthun, et al. Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder J Natl Cancer Inst, October 6, 2004; 96(19): 1447 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhu, J.-W. Huang, P.-H. Tseng, Y.-T. Yang, J. Fowble, C.-W. Shiau, Y.-J. Shaw, S. K. Kulp, and C.-S. Chen From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors Cancer Res., June 15, 2004; 64(12): 4309 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, and H. Mukhtar Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., May 1, 2004; 64(9): 3334 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, F. O. Ranelletti, F. Legge, M. Gessi, V. Salutari, M. G. Distefano, L. Lauriola, G. F. Zannoni, E. Martinelli, and G. Scambia Prognostic Role of the Ratio between Cyclooxygenase-2 in Tumor and Stroma Compartments in Cervical Cancer Clin. Cancer Res., May 1, 2004; 10(9): 3117 - 3123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Bottone Jr, J. M. Martinez, B. Alston-Mills, and T. E. Eling Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells Carcinogenesis, March 1, 2004; 25(3): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood, March 1, 2004; 103(5): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Kulp, Y.-T. Yang, C.-C. Hung, K.-F. Chen, J.-P. Lai, P.-H. Tseng, J. W. Fowble, P. J. Ward, and C.-S. Chen 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells Cancer Res., February 15, 2004; 64(4): 1444 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kazanov, H. Dvory-Sobol, M. Pick, E. Liberman, L. Strier, E. Choen-Noyman, V. Deutsch, T. Kunik, and N. Arber Celecoxib But Not Rofecoxib Inhibits the Growth of Transformed Cells in Vitro Clin. Cancer Res., January 1, 2004; 10(1): 267 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al. Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, F. O. Ranelletti, F. Legge, L. Lauriola, V. Salutari, M. Gessi, A. C. Testa, U. Werner, P. Navarra, G. Tringali, et al. Celecoxib Modulates the Expression of Cyclooxygenase-2, Ki67, Apoptosis-Related Marker, and Microvessel Density in Human Cervical Cancer: A Pilot Study Clin. Cancer Res., October 1, 2003; 9(12): 4324 - 4331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Bottone Jr., J. M. Martinez, J. B. Collins, C. A. Afshari, and T. E. Eling Gene Modulation by the Cyclooxygenase Inhibitor, Sulindac Sulfide, in Human Colorectal Carcinoma Cells: POSSIBLE LINK TO APOPTOSIS J. Biol. Chem., July 3, 2003; 278(28): 25790 - 25801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. DuBois New Agents for Cancer Prevention J Natl Cancer Inst, December 4, 2002; 94(23): 1732 - 1733. [Full Text] [PDF]
|
|